ENVERIC BIOSCIENCES COMPLETES PRIVATE PLACEMENT OF UP TO $13.9 MILLION PRICED AT MARKET VALUE UNDER NASDAQ REGULATIONS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ENVB?
Source: moomoo
Company Announcement: Enveric Biosciences has announced the closing of a private placement.
Funding Amount: The private placement raised up to $13.9 million.
Market Compliance: The funding was conducted under NASDAQ rules.
Investment Purpose: The raised funds are expected to support the company's ongoing projects and initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENVB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENVB
About ENVB
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ENVERIC BIOSCIENCES COMPLETES PRIVATE PLACEMENT OF UP TO $13.9 MILLION PRICED AT MARKET VALUE UNDER NASDAQ REGULATIONS
Company Announcement: Enveric Biosciences has announced the closing of a private placement.
Funding Amount: The private placement raised up to $13.9 million.
Market Compliance: The funding was conducted under NASDAQ rules.
Investment Purpose: The raised funds are expected to support the company's ongoing projects and initiatives.
See More
Enveric Biosciences Closes $5 Million Financing
- Financing Size: Enveric Biosciences successfully closed a $5 million private placement, issuing 2,222,223 shares of common stock and associated warrants, reflecting market confidence in its novel neurotherapeutics.
- Potential Proceeds: If the warrants are fully exercised, the company could receive approximately $8.9 million in additional proceeds, which will significantly support product development and operational funding.
- Use of Funds: The company intends to utilize the net proceeds for product development, working capital, and general corporate purposes, aiming to accelerate the clinical progress of its neuroplasticity therapies.
- Market Compliance: This financing was conducted under Section 4(a)(2) of the Securities Act of 1933, ensuring compliance, while the company has committed to filing a registration statement with the SEC for the resale of the unregistered securities.
See More
Enveric Plans to Fund Product Development Through Offering
- Clear Funding Purpose: Enveric aims to raise approximately $5 million from this offering to support product development and meet working capital and general corporate needs, indicating the company's focus on future growth.
- Share Issuance Details: The company will issue 2.2 million shares of common stock at a price of $2.25 per share, representing a discount of over 4% compared to Thursday's closing price, which is expected to lead to a nearly 13% drop in stock price during pre-market trading, potentially marking the largest decline in over 10 weeks.
- Warrant Exercise Potential: Investors have the option to exercise Series I and short-term Series J warrants at a strike price of $2 per share, which, if fully exercised, could provide an additional $8.9 million in funding, further enhancing the company's financial flexibility.
- Strengthened Patent Protection: Enveric recently secured a new U.S. patent for its EVM301 series of drug candidates, particularly EB-003, which aims to treat mental health disorders, showcasing the company's R&D potential and competitive edge in the mental health pharmaceutical market.
See More
Enveric Biosciences Announces Stock Offering Plan
- Offering Details: Enveric Biosciences has announced the sale of 2.22 million shares of common stock or pre-funded warrants, along with Series I and short-term Series J warrants at $2.25 per share, expecting total gross proceeds of approximately $5 million, indicating the company's proactive approach to capital raising.
- Warrant Potential: If fully exercised, the Series I and Series J warrants could add about $8.9 million more, although there is no guarantee of their exercise, reflecting the company's cautious stance on future financing.
- Use of Proceeds: The net proceeds from this offering will be allocated for product development, working capital, and general corporate purposes, demonstrating the company's strategic intent to drive business growth and innovation.
- Expected Closing Date: The offering is anticipated to close around April 17, 2026, indicating the company's strategic timing and planning for future developments.
See More
Enveric Biosciences Secures $5 Million in Private Placement Financing
- Financing Size: Enveric Biosciences has entered into agreements for the private placement of 2,222,223 shares of common stock and associated warrants, expected to raise approximately $5 million initially, with potential total proceeds of $8.9 million if warrants are fully exercised, enhancing liquidity for R&D support.
- Warrant Details: The issued warrants include Series I and Series J, with an exercise price of $2.00 per share, where Series I is valid for five years and Series J for 18 months, providing future funding flexibility to support ongoing development in the biotechnology sector.
- Use of Proceeds: The company intends to utilize the net proceeds for product development, working capital, and general corporate purposes, ensuring competitiveness in a rapidly evolving market while advancing its drug development pipeline.
- Market Compliance: This securities offering is conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious approach to compliance and highlighting potential market risks ahead.
See More
Enveric Biosciences Reports Q4 2025 Financial Results
- Financial Overview: Enveric Biosciences reported a GAAP EPS of -$6.12 for Q4 2025, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $4.7 million in cash on hand, suggesting that its liquidity may be insufficient to support future operations and R&D activities under the current financial circumstances.
- Funding Situation: Throughout 2025, the company raised gross proceeds of $12.2 million through various offerings, which, while alleviating short-term cash pressures, remains inadequate to cover ongoing losses.
- Market Reaction: Following Gilgamesh's withdrawal of its patent petition, Enveric's stock saw a rise; however, the announcement of a $1.5 million registered direct offering and warrant placement led to a decline in share price, reflecting market concerns about the company's long-term prospects.
See More
ENVERIC BIOSCIENCES COMPLETES PRIVATE PLACEMENT OF UP TO $13.9 MILLION PRICED AT MARKET VALUE UNDER NASDAQ REGULATIONS
Company Announcement: Enveric Biosciences has announced the closing of a private placement.
Funding Amount: The private placement raised up to $13.9 million.
Market Compliance: The funding was conducted under NASDAQ rules.
Investment Purpose: The raised funds are expected to support the company's ongoing projects and initiatives.
See More
Enveric Biosciences Closes $5 Million Financing
- Financing Size: Enveric Biosciences successfully closed a $5 million private placement, issuing 2,222,223 shares of common stock and associated warrants, reflecting market confidence in its novel neurotherapeutics.
- Potential Proceeds: If the warrants are fully exercised, the company could receive approximately $8.9 million in additional proceeds, which will significantly support product development and operational funding.
- Use of Funds: The company intends to utilize the net proceeds for product development, working capital, and general corporate purposes, aiming to accelerate the clinical progress of its neuroplasticity therapies.
- Market Compliance: This financing was conducted under Section 4(a)(2) of the Securities Act of 1933, ensuring compliance, while the company has committed to filing a registration statement with the SEC for the resale of the unregistered securities.
See More
Enveric Plans to Fund Product Development Through Offering
- Clear Funding Purpose: Enveric aims to raise approximately $5 million from this offering to support product development and meet working capital and general corporate needs, indicating the company's focus on future growth.
- Share Issuance Details: The company will issue 2.2 million shares of common stock at a price of $2.25 per share, representing a discount of over 4% compared to Thursday's closing price, which is expected to lead to a nearly 13% drop in stock price during pre-market trading, potentially marking the largest decline in over 10 weeks.
- Warrant Exercise Potential: Investors have the option to exercise Series I and short-term Series J warrants at a strike price of $2 per share, which, if fully exercised, could provide an additional $8.9 million in funding, further enhancing the company's financial flexibility.
- Strengthened Patent Protection: Enveric recently secured a new U.S. patent for its EVM301 series of drug candidates, particularly EB-003, which aims to treat mental health disorders, showcasing the company's R&D potential and competitive edge in the mental health pharmaceutical market.
See More
Enveric Biosciences Announces Stock Offering Plan
- Offering Details: Enveric Biosciences has announced the sale of 2.22 million shares of common stock or pre-funded warrants, along with Series I and short-term Series J warrants at $2.25 per share, expecting total gross proceeds of approximately $5 million, indicating the company's proactive approach to capital raising.
- Warrant Potential: If fully exercised, the Series I and Series J warrants could add about $8.9 million more, although there is no guarantee of their exercise, reflecting the company's cautious stance on future financing.
- Use of Proceeds: The net proceeds from this offering will be allocated for product development, working capital, and general corporate purposes, demonstrating the company's strategic intent to drive business growth and innovation.
- Expected Closing Date: The offering is anticipated to close around April 17, 2026, indicating the company's strategic timing and planning for future developments.
See More
Enveric Biosciences Secures $5 Million in Private Placement Financing
- Financing Size: Enveric Biosciences has entered into agreements for the private placement of 2,222,223 shares of common stock and associated warrants, expected to raise approximately $5 million initially, with potential total proceeds of $8.9 million if warrants are fully exercised, enhancing liquidity for R&D support.
- Warrant Details: The issued warrants include Series I and Series J, with an exercise price of $2.00 per share, where Series I is valid for five years and Series J for 18 months, providing future funding flexibility to support ongoing development in the biotechnology sector.
- Use of Proceeds: The company intends to utilize the net proceeds for product development, working capital, and general corporate purposes, ensuring competitiveness in a rapidly evolving market while advancing its drug development pipeline.
- Market Compliance: This securities offering is conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious approach to compliance and highlighting potential market risks ahead.
See More
Enveric Biosciences Reports Q4 2025 Financial Results
- Financial Overview: Enveric Biosciences reported a GAAP EPS of -$6.12 for Q4 2025, indicating significant challenges in profitability that could undermine investor confidence.
- Cash Position: As of December 31, 2025, the company had $4.7 million in cash on hand, suggesting that its liquidity may be insufficient to support future operations and R&D activities under the current financial circumstances.
- Funding Situation: Throughout 2025, the company raised gross proceeds of $12.2 million through various offerings, which, while alleviating short-term cash pressures, remains inadequate to cover ongoing losses.
- Market Reaction: Following Gilgamesh's withdrawal of its patent petition, Enveric's stock saw a rise; however, the announcement of a $1.5 million registered direct offering and warrant placement led to a decline in share price, reflecting market concerns about the company's long-term prospects.
See More
